Balversa 5 MG tablet 28S
Ended Awarded
- Contract number
- SPE2DB25FKA12
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,015
Award facts
- Contract value 100% obligated
- $16,014.51 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $16,014.51 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Balversa 5 mg tablets (28-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 10, 2025. Performance will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The company maintains an extensive portfolio of federal contract awards with the Defense Logistics Agency covering diverse therapeutic domains including specialty medications, brand-name and generic drugs, vaccines, and medical supplies. All reviewed contract awards have been competitively awarded with firm fixed pricing structures, demonstrating the company's capability to meet federal procurement requirements. The Pharmaceutical Prime Vendor Global Program Generation V contracts, under which this award falls, represent the DLA's strategic approach to establishing multiple regional pharmacy supply agreements with different contractors to ensure comprehensive global pharmaceutical support.
Quick answers
Who was awarded contract SPE2DB25FKA12?
SPE2DB25FKA12 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 19, 2025.
How much is contract SPE2DB25FKA12 worth?
The government has obligated $16,015 on SPE2DB25FKA12.
Is contract SPE2DB25FKA12 an order under another contract?
Yes. SPE2DB25FKA12 is a delivery order under SPE2DB22D2206, an indefinite delivery contract.
Was contract SPE2DB25FKA12 competed?
The extent of competition for SPE2DB25FKA12 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award